AbCellera Biologics Cash Flow Statement
NASDAQ: ABCLHealth CareBiotechnology: Pharmaceutical PreparationsUSD
12.55+0.525 (+4.37%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
AbCellera Biologics free cash flow
In fiscal 2025, AbCellera Biologics generated -$131.3 million of operating cash flow and spent $42.8 million on capital expenditures. That left free cash flow of -$174.1 million, a free-cash-flow margin of -231.7% of revenue.
Summary generated from market data by MetaCap's automated system. Methodology
AbCellera Biologics cash flow statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 |
|---|---|---|---|---|---|---|---|
| Net Income | -146.41M | -162.86M | -146.40M | 158.52M | 153.46M | 118.92M | -2.21M |
| Net Income growth (YoY) | — | — | -192.35% | +3.29% | +29.05% | — | — |
| Depreciation & Amortization | 18.44M | 12.54M | 24.39M | 27.84M | 14.45M | 4.84M | 1.60M |
| Stock-Based Compensation | 55.79M | 67.58M | 64.18M | 49.48M | 30.65M | 8.40M | 890.00K |
| Change in Working Capital | -37.21M | -66.46M | -56.76M | -20.00M | -32.14M | 16.34M | -1.81M |
| Operating Cash Flow | -131.29M | -108.56M | -43.88M | 277.36M | 244.58M | 22.69M | 2.69M |
| Capital Expenditures | -42.77M | -78.40M | -76.95M | -70.66M | -58.45M | -9.67M | -4.00M |
| Investing Cash Flow | 87.75M | 121.41M | -221.11M | -352.63M | -332.25M | -119.78M | -5.78M |
| Debt Issued | — | — | — | — | 872.00K | 15.49M | 193.00K |
| Debt Repaid | — | — | — | — | -1.82M | -19.94M | -399.00K |
| Financing Cash Flow | 14.08M | 12.77M | 10.36M | -1.63M | -3.89M | 683.65M | 195.00K |
| Net Change in Cash | -28.37M | 23.00M | -254.04M | -86.49M | -92.97M | 586.56M | -2.89M |
| Free Cash Flow | -174.07M | -186.95M | -120.82M | 206.70M | 186.13M | 13.02M | -1.30M |
This table shows 7 annual periods of AbCellera Biologics's cash flow statement, from FY 2025 back to FY 2019, across 12 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow ABCL's reporting calendar. What is a cash flow statement?